Table 3.
Reported outcomes for SAA patients who received Haplo-SCT
| Study | N | Age, median
(range), yr |
Conditioning
regimen |
Graft | Graft
failure＊＊, % |
Acute
GVHD†, % |
Chronic
GVHD, % |
OS, % |
|---|---|---|---|---|---|---|---|---|
| Im et al. (2013)31 | 12 | 13 (3-21) | Flu+Cy+ATG ±TBI | Ex vivo CD3-depleted PB | 20 | 33 | 22 | 100 at 1 yr |
| Gao et al. (2014)35 | 26 | 25 (18-41) | Flu+Cy+ATG | Unmanipulated PB + BM | 4 | 12 | 40 | 85 at 3 yr |
| Wang et al. (2014)36 | 17 | 10 (4-19) | Bu+Flu+Cy+ATG | Unmanipulated PB + BM | 6 | 29 | 27 | 72 at 1 yr |
| Clay et al. (2014)37 | 8 | 32 (19-57) | Flu+Cy+TBI | Unmanipulated PB | 25 | 13 | 0 | 63 at 1 yr |
| Esteves. (2015)38 | 16 | 17 (5-39) | Flu+Cy+TBI | Unmanipulated PB or BM | 13 | 13 | 20 | 67 at 1 yr |
| Xu et al. (2016)40‡ | 101 | 19 (2-45) | Flu+Cy+ATG | Unmanipulated PB + BM＊ | 6 | 34 | 26 | 89 at 3 yr |
| Xu et al. (2017)41‡ | 89 | 22 (4-51) | Flu+Cy+ATG | Unmanipulated PB + BM＊ | 1 | 30 | 39 at 3 yr | 86 at 3 yr |
| Xu et al. (2017)68‡ | 52 | 9 (2-17) | Flu+Cy+ATG | Unmanipulated PB + BM | 6 | 39 | 38 | 85 at 3 yr |
GVHD, acute graft-versus-host disease; OS, overall survival; Flu, fludarabine; Cy, cyclophosphamide; ATG, anti-thymocyte globulin; TBI, Total body irradiation.
＊Majority of patients received unmanipulated PB + BM.
＊＊Primary and secondary graft failure
†Acute GVHD≥grade 2
‡Three are different studies in terms of study design and study subjects.